D
Sell
3/8/2024Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to D- from E+ on 3/8/2024 due to a noticeable increase in the total return index, valuation index and volatility index.
E
Sell
11/10/2023Downgrade
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to E+ from D- on 11/10/2023 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 6.29 to 13.94, EBIT declined 20.35% from -$13.28M to -$15.98M, and earnings per share declined from -$0.1227 to -$0.1445.
D
Sell
4/13/2023Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to D- from E+ on 4/13/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 2.52 to 4.17.
D
Sell
2/23/2023Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index. Debt to equity increased from 1.87 to 2.52, and the quick ratio declined from 2.13 to 1.76.
D
Sell
11/1/2022Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to D from D- on 11/1/2022 due to an increase in the growth index. Operating cash flow increased 57.43% from -$48.41M to -$20.61M, EBIT increased 34.94% from -$29.07M to -$18.92M, and earnings per share increased from -$0.2497 to -$0.1932.
D
Sell
7/1/2022Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to D- from E on 07/01/2022.
E
Sell
6/23/2022Downgrade
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to E from E+ on 6/23/2022 due to a large decline in the total return index, volatility index and growth index. Operating cash flow declined 67.24% from -$28.95M to -$48.41M.
E
Sell
4/1/2022Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to E+ from E on 4/1/2022 due to an increase in the total return index.
E
Sell
3/15/2022Upgraded
Xeris Biopharma Holdings, Inc. (XERS) was upgraded to E from E- on 3/15/2022 due to a noticeable increase in the total return index, solvency index and valuation index.
E
Sell
1/25/2022Downgrade
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to E- from E on 1/25/2022 due to a decline in the volatility index.
E
Sell
12/30/2021None
Xeris Biopharma Holdings, Inc. (XERS) was downgraded to E from U on 12/30/2021.
